Status:
UNKNOWN
Safety and Tolerability Study of Levetiracetam to Treat Patients With Status Epilepticus
Lead Sponsor:
Medical Center Haaglanden
Collaborating Sponsors:
UCB Pharma
Conditions:
Status Epilepticus
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether levetiracetam is safe and well tolerated by patients while suffering a status epilepticus. Levetiracetam is added to the standard treatment of patient...
Detailed Description
Status epilepticus (SE) is a disorder with high mortality and morbidity. There are strong indications that ongoing seizure activity substantially reduces the chances on a good outcome. This implies th...
Eligibility Criteria
Inclusion
- Age: ≥18 years of age
- All types of SE, diagnosed by the medical examiner according to the predefined definition. Absence SE has to be confirmed by EEG.
- Woman: 18-50 years of age of whom is known, from anamnesis or hetero-anamnesis (first line relative), that she is not pregnant.
Exclusion
- Woman \< 50 years of age, without information on pregnancy
- Known pregnancy
- Known allergy for levetiracetam
- Daily dose levetiracetam of more than 2000mg/day
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
End Date :
April 1 2008
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00362141
Start Date
October 1 2006
End Date
April 1 2008
Last Update
April 2 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Centre Haaglanden
The Hague, South Holland, Netherlands, 2512VA